2017-2018 Drug Approvals in Solid Tumors
Presented by Patrick J. Kiel, PharmD, BCPS, BCOP
Indiana University Simon Cancer Center, Indianapolis, Indiana
Presenter’s disclosures of conflicts of interest are found at the end of this article.
J Adv Pract Oncol 2019;10(3):218–224 |
© 2019 Harborside™
New oncology approvals from 2017 to 2018 were mostly for additional indications, with many agents moved up to first-line therapy. Patrick J. Kiel, PharmD, BCPS, BCOP, detailed their implications for advanced practice.
For access to the full length article, please sign in